Abstract
Precision medicine just witnessed two breakthroughs in oncology in 2017. Pembrolizumab (Keytruda), Merck's antiprogrammed cell death-1 (PD-1) monoclon......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
